Allergan Inc. Buys Co-Promotion Rights on MAP Pharmaceuticals, Inc. Migraine Drug; Deal Worth up to $157M

January 31, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BANGALORE, Jan 31 (Reuters) - Allergan Inc (AGN.N) bought co-promotion rights on Map Pharmaceuticals Inc's (MAPP.O) experimental treatment for acute migraine for $60 million in upfront payment, in a move to expand its migraine franchise.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions Asia